Senate slaps Medicare on anemia drug coverage in Amgen win

Share this article:

Spurred by a strong lobbying effort by Amgen, the Senate on Tuesday called on the Centers for Medicare and Medicaid Services to reconsider its decision to restrict coverage of Epogen and Aranesp.

CMS's July move on the Amgen anemia drugs prompted major layoffs at the Thousand Oaks, CA company.

As the resolution, sponsored by Sens. Arlen Specter (R-PA) and Frank Lautenberg (D-NJ), was non-binding, it is unclear how much pressure it will place on CMS to reverse its decision.
Amgen also has the American Society of Clinical Oncology on its side. The society recently said the restriction interferes with physicians' ability to care for patients suffering from anemia.

Share this article:

Email Newsletters

More in News

Astellas, DOJ settle for $7.3M

Astellas, DOJ settle for $7.3M

Astellas has settled a False Claims case with the Department of Justice over the 2010-2013 marketing of an antifungal medication. Astellas denies the allegations.

Boehringer drug lands US, EU orphan tag

Boehringer drug lands US, EU orphan tag

The experimental Breakthrough Therapy treatment is for acute myeloid leukemia.

Omnio app moves to smartphones

Omnio app moves to smartphones

Physicians Interactive is introducing the third wave of its Omnio app, making the tablet-only tool available for iPhones and Android phones.